We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

March 11, 2005

In re Forest Laboratories, Inc. Securities Litigation

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. February 2, 2009

    Coughlin Stoia Attys Seek $18M In Celexa Deal Fees

    Lead counsel for the plaintiffs in a securities class action alleging that Forest Laboratories Inc. provided misleading information about the safety of its blockbuster antidepressants Celexa and Lexapro have asked for more than $18 million in fees and expenses.

3 other articles on this case. View all »

Parties

To view the parties, register now.